Dopamine Uptake Inhibitors

"Dopamine Uptake Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.

Descriptor ID	D018765
MeSH Number(s)	D27.505.519.562.437.220 D27.505.519.625.150.800 D27.505.519.625.600.220 D27.505.696.577.150.800 D27.505.696.577.600.220
Concept/Terms	Dopamine Uptake Inhibitors Dopamine Uptake Inhibitors Reuptake Inhibitors, Dopamine Inhibitors, Dopamine Uptake Uptake Inhibitors, Dopamine Inhibitors, Dopamine Reuptake Dopamine Reuptake Inhibitors

Below are MeSH descriptors whose meaning is more general than "Dopamine Uptake Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Membrane Transport Modulators [D27.505.519.562]
Neurotransmitter Uptake Inhibitors [D27.505.519.562.437]
Dopamine Uptake Inhibitors [D27.505.519.562.437.220]
Neurotransmitter Agents [D27.505.519.625]
Dopamine Agents [D27.505.519.625.150]
Dopamine Uptake Inhibitors [D27.505.519.625.150.800]
Neurotransmitter Uptake Inhibitors [D27.505.519.625.600]
Dopamine Uptake Inhibitors [D27.505.519.625.600.220]
Physiological Effects of Drugs [D27.505.696]
Neurotransmitter Agents [D27.505.696.577]
Dopamine Agents [D27.505.696.577.150]
Dopamine Uptake Inhibitors [D27.505.696.577.150.800]
Neurotransmitter Uptake Inhibitors [D27.505.696.577.600]
Dopamine Uptake Inhibitors [D27.505.696.577.600.220]

Below are MeSH descriptors whose meaning is related to "Dopamine Uptake Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Dopamine Uptake Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dopamine Uptake Inhibitors" by people in this website by year, and whether "Dopamine Uptake Inhibitors" was a major or minor topic of these publications.

Bar chart showing 61 publications over 23 distinct years, with a maximum of 6 publications in 2001 and 2008 and 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1999	1	0	1
2000	0	1	1
2001	6	0	6
2002	3	0	3
2003	0	1	1
2004	2	1	3
2005	3	0	3
2006	1	3	4
2007	1	0	1
2008	4	2	6
2009	4	1	5
2010	1	1	2
2011	3	0	3
2012	1	0	1
2013	1	1	2
2014	4	2	6
2015	2	0	2
2016	2	0	2
2017	3	1	4
2018	1	0	1
2020	2	0	2
2021	0	1	1

Below are the most recent publications written about "Dopamine Uptake Inhibitors" by people in Profiles.

Beltran NM, Ramos J, Galindo KI, Echeverri Alegre JI, Cruz B, Hernandez-Casner C, Serafine KM. Intermittent dietary supplementation with fish oil prevents high fat diet-induced enhanced sensitivity to dopaminergic drugs. Behav Pharmacol. 2021 02 01; 32(1):9-20.

View in: PubMed
Bennett A, Barrera E, Namballa H, Harding W, Ranaldi R. (-)-Stepholidine blocks expression, but not development, of cocaine conditioned place preference in rats. Neurosci Lett. 2020 08 24; 734:135151.

View in: PubMed
Yorgason JT, Hedges DM, Obray JD, Jang EY, Bills KB, Woodbury M, Williams B, Parsons MJ, Andres MA, Steffensen SC. Methamphetamine increases dopamine release in the nucleus accumbens through calcium-dependent processes. Psychopharmacology (Berl). 2020 May; 237(5):1317-1330.

View in: PubMed
Doncheck EM, Hafenbreidel M, Ruder SA, Fitzgerald MK, Torres L, Mueller D. bFGF expression is differentially regulated by cocaine seeking versus extinction in learning-related brain regions. Learn Mem. 2018 08; 25(8):361-368.

View in: PubMed
Elkashef A, Bra?ic JR, Cantelina LR, Kahn R, Chiang N, Ye W, Zhou Y, Mojsiak J, Warren KR, Crabb A, Hilton J, Wong DF, Vocci F. A cholecystokinin B receptor antagonist and cocaine interaction, phase I study. CNS Neurosci Ther. 2019 01; 25(1):136-146.

View in: PubMed
Beaudoin GMJ, Gomez JA, Perkins J, Bland JL, Petko AK, Paladini CA. Cocaine Selectively Reorganizes Excitatory Inputs to Substantia Nigra Pars Compacta Dopamine Neurons. J Neurosci. 2018 01 31; 38(5):1151-1159.

View in: PubMed
Sepulveda-Orengo MT, Healey KL, Kim R, Auriemma AC, Rojas J, Woronoff N, Hyppolite R, Reissner KJ. Riluzole Impairs Cocaine Reinstatement and Restores Adaptations in Intrinsic Excitability and GLT-1 Expression. Neuropsychopharmacology. 2018 05; 43(6):1212-1223.

View in: PubMed
Kim R, Sepulveda-Orengo MT, Healey KL, Williams EA, Reissner KJ. Regulation of glutamate transporter 1 (GLT-1) gene expression by cocaine self-administration and withdrawal. Neuropharmacology. 2018 Jan; 128:1-10.

View in: PubMed
Dash S, Balasubramaniam M, Rana T, Godino A, Peck EG, Goodwin JS, Villalta F, Calipari ES, Nestler EJ, Dash C, Pandhare J. Poly (ADP-Ribose) Polymerase-1 (PARP-1) Induction by Cocaine Is Post-Transcriptionally Regulated by miR-125b. eNeuro. 2017 Jul-Aug; 4(4).

View in: PubMed
Otis JM, Mueller D. Reversal of Cocaine-Associated Synaptic Plasticity in Medial Prefrontal Cortex Parallels Elimination of Memory Retrieval. Neuropsychopharmacology. 2017 Sep; 42(10):2000-2010.

View in: PubMed

People

Explore

Similar Concepts

Top Journals